547 related articles for article (PubMed ID: 20104194)
1. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
[TBL] [Abstract][Full Text] [Related]
3. Tumor characteristics, expressions of ERCC1, Bax, p53, IGF1R, Bcl2, Bcl2/Bax and prognostic factors for overall survival in patients with lung carcinoid.
Velinovic M; Jankovic R; Jovanovic D; Skodric Trifunovic V; Gavrilovic D; Stojsic J; Cavic M
J BUON; 2019; 24(1):256-266. PubMed ID: 30941978
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine neoplasms of the lung: a prognostic spectrum.
Asamura H; Kameya T; Matsuno Y; Noguchi M; Tada H; Ishikawa Y; Yokose T; Jiang SX; Inoue T; Nakagawa K; Tajima K; Nagai K
J Clin Oncol; 2006 Jan; 24(1):70-6. PubMed ID: 16382115
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Neubauer E; Wirtz RM; Kaemmerer D; Athelogou M; Schmidt L; Sänger J; Lupp A
Oncotarget; 2016 Jul; 7(27):41959-41973. PubMed ID: 27259241
[TBL] [Abstract][Full Text] [Related]
7. [Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].
Schnabel PA; Junker K
Pathologe; 2015 May; 36(3):283-92. PubMed ID: 25956813
[TBL] [Abstract][Full Text] [Related]
8. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary atypical carcinoid: predictors of survival in 106 cases.
Beasley MB; Thunnissen FB; Brambilla E; Hasleton P; Steele R; Hammar SP; Colby TV; Sheppard M; Shimosato Y; Koss MN; Falk R; Travis WD
Hum Pathol; 2000 Oct; 31(10):1255-65. PubMed ID: 11070119
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
Yeh YC; Chou TY
J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications.
Sereno M; Cejas P; Moreno V; Belda-Iniesta C; López R; Nistal M; Feliu J; De Castro Carpeño J
Int J Oncol; 2012 Jun; 40(6):2104-10. PubMed ID: 22344449
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
[TBL] [Abstract][Full Text] [Related]
13. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
15. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome.
Walter RF; Mairinger FD; Werner R; Vollbrecht C; Hager T; Schmid KW; Wohlschlaeger J; Christoph DC
Oncotarget; 2016 Apr; 7(15):20166-79. PubMed ID: 27064343
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
17. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
[TBL] [Abstract][Full Text] [Related]
18. Advances in neuroendocrine lung tumors.
Travis WD
Ann Oncol; 2010 Oct; 21 Suppl 7():vii65-71. PubMed ID: 20943645
[TBL] [Abstract][Full Text] [Related]
19. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
Travis WD; Rush W; Flieder DB; Falk R; Fleming MV; Gal AA; Koss MN
Am J Surg Pathol; 1998 Aug; 22(8):934-44. PubMed ID: 9706973
[TBL] [Abstract][Full Text] [Related]
20. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
